Research Paper Volume 15, Issue 5 pp 1685—1698
Signatures of immune cell infiltration for predicting immune escape and immunotherapy in cervical cancer
Figure 7. The additional validation and prediction in immune escape and immunotherapy. (A) The Additional Validation with TIDE scores in two ICI score group. (B) The immunotherapy response of anti-PD-L1 in the IMvigor210. (C) Survival plots of ICI scores in the IMvigor210. The responses of IPS-CTLA4 (D), IPS-PD1 (E) and IPS-PD1 and CTLA4 (F) in two ICI score groups. The sensitivities of Bosutinib (G), Dasatinib (H) and Belinostat (I) in two ICI score groups.